Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, 8200, Aarhus N, Denmark.
Br J Cancer. 2011 Jan 4;104(1):188-92. doi: 10.1038/sj.bjc.6605911. Epub 2010 Sep 28.
Earlier research suggests that use of selective serotonin reuptake inhibitors (SSRIs), but not tricyclic antidepressants (TCAs), reduces the risk of colorectal cancer (CRC).
We conducted a population-based case-control study to investigate the association between antidepressant use and CRC risk. Cases were diagnosed with a first primary CRC from 1991 through 2008. We selected 10 population controls matched to cases on sex, birth year, and residence from the Danish Civil Registration System using risk-set sampling. We estimated the odds ratios (ORs) and 95% confidence intervals (CIs) associating antidepressant use with colorectal cancer occurrence, controlling for potential confounders.
The study included 9,979 cases and 99,790 controls. We found no notable reduction in CRC risk in ever users (≥2 prescriptions) of TCAs (OR=0.94; 95% CI: 0.84, 1.05), SSRIs (OR=0.97; 95% CI: 0.90, 1.05), or other antidepressants (OR=0.95; 95% CI: 0.83, 1.07). Associations for recent and former use of antidepressants were also near null. Intensity of antidepressant use (number of pills divided by total duration of use), regardless of duration, was not associated with CRC risk.
We found no evidence that antidepressant use substantially reduces the risk of colorectal cancer.
早期研究表明，选择性 5-羟色胺再摄取抑制剂（SSRIs）的使用可以降低结直肠癌（CRC）的风险，但三环类抗抑郁药（TCAs）则没有。
我们进行了一项基于人群的病例对照研究，以调查抗抑郁药使用与 CRC 风险之间的关联。病例是在 1991 年至 2008 年期间首次被诊断为原发性 CRC。我们使用风险集抽样从丹麦民事登记系统中选择了 10 名与病例性别、出生年份和居住地相匹配的人群对照。我们估计了与使用抗抑郁药与结直肠癌发生相关的比值比（OR）和 95%置信区间（CI），同时控制了潜在的混杂因素。
这项研究包括 9979 例病例和 99790 例对照。我们发现，使用 TCA（≥2 个处方）（OR=0.94；95%CI：0.84，1.05）、SSRIs（OR=0.97；95%CI：0.90，1.05）或其他抗抑郁药（OR=0.95；95%CI：0.83，1.07）的患者 CRC 风险没有显著降低。近期和既往使用抗抑郁药的相关性也接近零。抗抑郁药使用的强度（服用的药丸数除以使用的总持续时间），无论持续时间如何，均与 CRC 风险无关。
我们没有发现抗抑郁药使用能显著降低结直肠癌风险的证据。
